IOTA Pharmaceuticals


IOTA Pharmaceuticals
Fragment - based Drug Discovery
GBM Drug Bank
Glioma & Glioblastoma
WINDOW on Glioblastoma
IOTA Pharmaceuticals
May 01, 2018

IOTA participates in the design of novel antiparasitic agents

Together with colleagues from the PDE4NPD Consortium, IOTA scientist Dr David Bailey has participated in the design and optimisation of new antiparasitic lead molecules targeting parasite phosphodiesterases. Read the full report of this work in the Journal of Medicinal Chemistry here, and more about IOTA’s phosphodiesterase drug discovery strategy here.